Velocity of Content

FEBRUARY 23, 2022

And, like many other people, we find podcasts are an efficient and effective means of keeping up on science topics of interest. In Machines We Trust (MIT) A pro-technology series that takes on future-facing topics. The Antigen (Pfizer) Explaining how vaccines are developed, and how they work.

Technology 116

Technology Publishing Business Copyright 116

SpicyIP

NOVEMBER 8, 2023

Basheer, in his 2009 post, about Chantix, a Pfizer-patented anti-smoking drug, raised questions regarding transparency around the discretion to require local clinical trials. and Class 5.2 of our IP Reveries series , while discussing the basics of clinical trials and drug innovation, have highlighted their implications.

Trademark 59

Trademark Publishing Journalism Copyright 59

IPilogue

JANUARY 14, 2022

On July 28, 2021, the Federal Court of Appeal confirmed overbreadth as a standalone attack on patent validity: Seedlings Life Science Ventures, LLC v Pfizer Canada ULC. Our hard-working students and community members published more than twice as many articles than in 2020 and the most articles in a calendar year since 2011.

IP 106

IP Copyright Infringement Inventor Intellectual Property 106

The IPKat

SEPTEMBER 12, 2022

This is the first in-person Congress since London hosted in 2019, so it was only apt that the first panel session was on the topic of IP and Covid-19. Eric highlighted the Pfizer/BioNTech collaboration as one such example. Wolf returned to the IP incentivization topic, but noted there was also the important “access” to vaccine issue.

Reporting 91

Reporting IP Contracts Licensing 91

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Pfizer announced plans to pursue interchangeable status for its adalimumab biosimilar Abrilada ™ in December 2021. Nyvepria ™ (Pfizer). Abrilada ™ (Pfizer). Nivestym ® (Pfizer/ Hospira). Retacrit ® (Pfizer/Hospira). Ixifi ® (Pfizer). No earlier than 2023 per settlement. Neulasta ® (Amgen). June 10, 2020.

Litigation 52

Litigation Settlement Patent Marketing 52

LexBlog IP

MARCH 12, 2023

Staying on the topic of Rule 12(b)(6) motions, during the course of my review of these cases each month, I am seeing a trend by federal courts denying these motions on the trade secret claims but sometimes dismissing other tort claims. Not in my court, ruled Magistrate Judge Thomas Farrish in Pfizer, Inc. Regor Therapeutics, Inc.

Blogging 52

Blogging Litigation Ownership Reporting 52